A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences

por Sri Bhashyam, Sumitra, Marsh, Kevin, Quartel, Adrian, Weng, Haoling H., Gershman, Ari, Longo, Nicola, Thomas, Janet, Zori, Roberto
Publicado 2019

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

por Combe, Bernard, Dasgupta, Bhaskar, Louw, Ingrid, Pal, Sarvajeet, Wollenhaupt, Jürgen, Zerbini, Cristiano A F, Beaulieu, Andre D, Schulze-Koops, Hendrik, Durez, Patrick, Yao, Ruji, Vastesaeger, Nathan, Weng, Haoling H
Publicado 2014

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials

por Gupta, Soumi, Lau, Kelly, Harding, Cary O., Shepherd, Gillian, Boyer, Ryan, Atkinson, John P., Knight, Vijaya, Olbertz, Joy, Larimore, Kevin, Gu, Zhonghu, Li, Mingjin, Rosen, Orli, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky
Publicado 2018

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

por Qi, Yulan, Patel, Gina, Henshaw, Joshua, Gupta, Soumi, Olbertz, Joy, Larimore, Kevin, Harding, Cary O., Merilainen, Markus, Zori, Roberto, Longo, Nicola, Burton, Barbara K., Li, Mingjin, Gu, Zhonghua, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky
Publicado 2021

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab

por Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Lazaro, María Alicia, Moots, Robert J., Wollenhaupt, Jürgen, Zerbini, Cristiano A. F., Louw, Ingrid, Combe, Bernard, Beaulieu, Andre, Schulze-Koops, Hendrik, Dasgupta, Bhaskar, Fu, Bo, Huyck, Susan, Weng, Haoling H., Govoni, Marinella, Durez, Patrick
Publicado 2016